Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 234 publications
Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.
Journal: Future oncology (London, England)
Published: August 30, 2026
International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 22, 2026
Time to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma.
Journal: The New England journal of medicine
Published: July 15, 2026
Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma.
Journal: Cancer
Published: July 07, 2026
De-escalation trials in multiple myeloma: past, present and future.
Journal: Nature reviews. Clinical oncology
Published: July 06, 2026
Real-World Treatment Patterns and Outcomes for Patients With Relapsed/Refractory Multiple Myeloma and Prior Exposure to Lenalidomide and Proteasome Inhibitors in the United States.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 01, 2026
Targeting BCMA in patients with relapsed/refractory multiple myeloma in 1 to 3 prior lines of therapy.
Journal: Blood advances
Published: February 26, 2026
Targeting BCMA in Patients with Relapsed/Refractory Multiple Myeloma in 1-3 Prior Lines of Therapy.
Journal: Blood advances
Published: February 26, 2026
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Journal: The New England journal of medicine
Published: December 09, 2025
Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation.
Journal: Cancer
Published: November 22, 2025
Last Updated: 09/26/2026